In patients with castration-resistant prostate cancers.

Aragon initiates dosing in ARN-509 Stage 1/2 clinical trial for castration-resistant prostate cancer Aragon Pharmaceuticals today announced the dosing of the first patient in a Stage 1/2 clinical trial of the company’s lead compound, ARN-509, in patients with castration-resistant prostate cancers . The Phase 1 portion of the study, being executed at the Memorial Sloan-Kettering Cancer Center in New York City, is an open-label, dose-escalating trial evaluating the tolerability and safety of ARN-509 in individuals with progressive metastatic castration-resistant prostate cancer.Patent for DualCap IV disinfection technology Catheter Connections, a start-up firm co-founded by nurses seeking to reduce deadly hospital-acquired bloodstream attacks, today the issuance of U announced.S. Patent No. 8 8,343,112. The Company has the only granted U.S. Patents for safeguarding and disinfecting ‘man luer’ connectors, which will be the connectors used for connecting IV tubing lines to IV catheters. THE BUSINESS provides pending lawsuits against Ivera Medical Company in the U.S. District Court of Utah, Central Division, where it accuses Ivera of infringing a few of its patents, unfair competition, deceptive practices and false advertising related to the advertising of Ivera's male luer disinfectant cap.S. District Court for the Southern District of California. As the California Court lately denied a demand to stay these fits without prejudice to submitting the request again, the stay has no effect upon the pending inter partes reexaminations in which the United States Patent and Trademark Workplace offers rejected each of Ivera's patent claims that reexamination was requested.

Other Posts From Category "tools":

Related Posts